These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 11348533)
1. Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis. Blum J; Nkunku S; Burri C Trop Med Int Health; 2001 May; 6(5):390-400. PubMed ID: 11348533 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Burri C; Nkunku S; Merolle A; Smith T; Blum J; Brun R Lancet; 2000 Apr; 355(9213):1419-25. PubMed ID: 10791526 [TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of the 10-day melarsoprol schedule for the treatment of second stage Rhodesiense sleeping sickness. Kuepfer I; Schmid C; Allan M; Edielu A; Haary EP; Kakembo A; Kibona S; Blum J; Burri C PLoS Negl Trop Dis; 2012 Aug; 6(8):e1695. PubMed ID: 22970329 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness. Schmid C; Nkunku S; Merolle A; Vounatsou P; Burri C Lancet; 2004 Aug 28-Sep 3; 364(9436):789-90. PubMed ID: 15337407 [TBL] [Abstract][Full Text] [Related]
5. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness. Bisser S; N'Siesi FX; Lejon V; Preux PM; Van Nieuwenhove S; Miaka Mia Bilenge C; Būscher P J Infect Dis; 2007 Feb; 195(3):322-9. PubMed ID: 17205469 [TBL] [Abstract][Full Text] [Related]
6. [Arsenical-induced encephalopathy during the treatment of African trypanosomiasis. Apropos of a case with a favorable outcome]. Pialoux G; Kernbaum S; Vachon F Bull Soc Pathol Exot Filiales; 1988; 81(3 Pt 2):555-6. PubMed ID: 3197251 [TBL] [Abstract][Full Text] [Related]
7. [2 epidemics of arsenical encephalopathy in the treatment of trypanosomiasis, Uganda, 1992-1993]. Ancelle T; Barret B; Flachet L; Moren A Bull Soc Pathol Exot; 1994; 87(5):341-6. PubMed ID: 7496198 [TBL] [Abstract][Full Text] [Related]
8. Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness. Pepin J; Milord F; Guern C; Mpia B; Ethier L; Mansinsa D Lancet; 1989 Jun; 1(8649):1246-50. PubMed ID: 2566790 [TBL] [Abstract][Full Text] [Related]
9. An alternative form of melarsoprol in sleeping sickness. Kennedy PG Trends Parasitol; 2012 Aug; 28(8):307-10. PubMed ID: 22704910 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Médecins Sans Frontières programmes. Balasegaram M; Young H; Chappuis F; Priotto G; Raguenaud ME; Checchi F Trans R Soc Trop Med Hyg; 2009 Mar; 103(3):280-90. PubMed ID: 18947846 [TBL] [Abstract][Full Text] [Related]
11. Human African trypanosomiasis: diagnosis, relapse and survival after severe melarsoprol-induced encephalopathy. Checkley AM; Pepin J; Gibson WC; Taylor MN; Jäger HR; Mabey DC Trans R Soc Trop Med Hyg; 2007 May; 101(5):523-6. PubMed ID: 17270227 [TBL] [Abstract][Full Text] [Related]
12. Randomized controlled trial of three regimens of melarsoprol in the treatment of Trypanosoma brucei gambiense trypanosomiasis. Pépin J; Mpia B Trans R Soc Trop Med Hyg; 2006 May; 100(5):437-41. PubMed ID: 16483622 [TBL] [Abstract][Full Text] [Related]
13. Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis. Chappuis F; Udayraj N; Stietenroth K; Meussen A; Bovier PA Clin Infect Dis; 2005 Sep; 41(5):748-51. PubMed ID: 16080099 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II). Schmid C; Richer M; Bilenge CM; Josenando T; Chappuis F; Manthelot CR; Nangouma A; Doua F; Asumu PN; Simarro PP; Burri C J Infect Dis; 2005 Jun; 191(11):1922-31. PubMed ID: 15871127 [TBL] [Abstract][Full Text] [Related]
15. Lesson of the month: a psychiatric diagnosis overturned by a blood film. Wise E; Easom N; Watson J; Bailey R; Brown M Clin Med (Lond); 2012 Jun; 12(3):295-6. PubMed ID: 22783788 [No Abstract] [Full Text] [Related]
16. Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment. Burri C; Keiser J Trop Med Int Health; 2001 May; 6(5):412-20. PubMed ID: 11348536 [TBL] [Abstract][Full Text] [Related]
17. Melarsoprol-free drug combinations for second-stage Gambian sleeping sickness: the way to go. Chappuis F Clin Infect Dis; 2007 Dec; 45(11):1443-5. PubMed ID: 17990226 [No Abstract] [Full Text] [Related]
19. Eflornithine is a cost-effective alternative to melarsoprol for the treatment of second-stage human West African trypanosomiasis in Caxito, Angola. Robays J; Raguenaud ME; Josenando T; Boelaert M Trop Med Int Health; 2008 Feb; 13(2):265-71. PubMed ID: 18304274 [TBL] [Abstract][Full Text] [Related]
20. Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness. Pépin J; Milord F; Khonde AN; Niyonsenga T; Loko L; Mpia B; De Wals P Trans R Soc Trop Med Hyg; 1995; 89(1):92-7. PubMed ID: 7747321 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]